THE INFLUENCE OF MOTOR FLUCTUATIONS ON PSYCHOEMOTIONAL STATUS AND QUALITY OF LIFE IN PARKINSON'S DISEASE
Abstract
Relevance. Parkinson's disease is a neurodegenerative disease of the nervous system and one of the most topical problems in neurology. Motor fluctuations are a common complication of long-term levodopa treatment in patients with Parkinson's disease. Рurpose of the study. To study the effect of motor fluctuations on the psychoemotional state and quality of life of patients with Parkinson's disease. Materials and methods of the study. The study included 120 patients with various clinical forms of Parkinson's disease. To compare the parameters during the study, the patients were divided into 2 groups: patients with motor fluctuations (55 people) and patients without motor fluctuations (65 people). All patients underwent clinical neurological and neuropsychological examinations. Research results. In the group with motor fluctuations, the comorbid form of affective disorders, that is, depression + anxiety, was significantly higher: in the group with fluctuations - 54.5% (30/55 patients), in the group without fluctuations - 24.6% (16/65 patients). When assessing the significance of this difference using the χ² test, the obtained value was p<0.01. Thus, it can be noted that motor fluctuations are strongly associated with more severe and comorbid forms of mental disorders (depression and anxiety). The results obtained based on the PDQ-39 scale domains show that psychoemotional disorders have varying degrees of negative impact on virtually all areas of life. Conclusion. When assessing quality of life using the PDQ-39 questionnaire, patients with anxiety and depression showed a significant decrease in indicators such as mobility, daily activities, emotional state, cognitive function, and social support. The greatest negative impact was observed in the group with comorbid depression and anxiety.
Keywords:
About the Authors
List of references
Akhmadeeva G.N., Tayupova G.N., Baytimerov A.R., Magzhanov R.V., Khidiyatova I.M., Khusnutdinova E.K. Study of possible risk factors for the development of anxiety-depressive disorders in patients with Parkinson's disease in the Republic of Bashkortostan. Kazan Neurological Bulletin named after A.N. Bekhterev. 2015; 1: 27-31.
Akhmadeeva G.N., Magzhanov R.V. Anxiety-depressive disorders in patients with Parkinson's disease in the Republic of Bashkortostan. Ural Medical Journal. 2015; 2: 44-48
Illarioshkin, S.N. (2015). Current Concepts on the Etiology of Parkinson's Disease // Neurological Journal. 2015. No. 4. pp. 4-13.
Levin O.S., Koloman I.I., Kulikov A.G. "Features of Thermoregulation in Patients with Parkinson's Disease". S.S. Korsakov Journal of Neurology and Psychiatry. 2022; 122(11-2): 19-23.
Timofeeva, A.A. (2016). Invasive Methods in the Treatment of Advanced Stages of Parkinson's Disease: Apomorphine, LCIG, and DBS - a Data Review. S.S. Korsakov Journal of Neurology and Psychiatry, 116(12), 54-60.
Khalimova H.M., Rashidova N.S., Aripov A.N., Matmurodov R.Zh. The role and importance of S100B oxil in the early detection of extrapyramidal diseases// Scientific and practical journal Neurology, Tashkent, 2015.-№4 (64).-P.11-14.
Aquino C. C., Fox S. H. Clinical spectrum of levodopa-induced complications // Mov. Disord. 2015. Vol. 30. N 1. P. 80–89.
Assogna FF, Fagioli S, Cravello L, Meco G, Pierantozzi M, Stefani A, Imperiale F, Caltagirone C, Pontieri FE, Spalletta G. Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses. Neuropsychiatr Dis Treat. 2013;9:389-396.
Ballanger, B., Strafella, A. P., & Carbon, M. Pimavanserin: Novel pharmacotherapy for Parkinson’s disease psychosis. Expert Opinion on Pharmacotherapy, 2024; 25(8), 1012-1022.
Dissanayaka W., Nadeeka N. Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson’s disease. Parkinsonism & Related Disorders, 36 (2017), 63-68.
Lopez, L., Fox, S. H. Motor- and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis. Frontiers in Neurology, 2022; 13, 919778.
Martinez-Martin, P., Rodríguez-Blázquez, C., Forjaz, M. J., et al. Motor fluctuations development is associated with non-motor symptoms burden progression in Parkinson’s disease patients: A 2-year follow-up study. Journal of Neurology, 2022; 269(4), 1685-1695.
Meltzer, H. Y., & Stahl, S. M. Pimavanserin in the treatment of Parkinson’s disease psychosis: Meta-analysis and meta-regression of randomized clinical trials. CNS Drugs, 2019; 33(6), 591-602.
Skogar O, Nilsson M. Distribution of non-motor symptoms in idiopathic Parkinson’s disease and secondary parkinsonism. J Multidiscip Healthc 2018;11. – P. 525–534.
Subramanian, I., & Sethi, K. D. (2023). Motor fluctuations in Parkinson disease – a mini-review of emerging drugs. Journal of Parkinson’s Disease, 2023, 13(1), 15-29.
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.